Latest Strategic Partnerships News

Talga Group’s application for a major Swedish government grant was declined due to budget constraints, yet the company remains on track with alternative financing to scale its graphite anode production.

MoneyMe Limited reported a 17.2% rise in gross revenue and a 43.7% reduction in net loss for the half-year to December 2025, underpinned by strong loan book growth and enhanced funding capacity.

Jameson Resources has marked significant progress in advancing its Crown Mountain steelmaking coal project, doubling its pre-tax NPV to US$942 million and moving closer to final environmental approvals and development permits expected by the end of 2026.

PLS Group reported a robust first half of FY26, with lithium production up 6% and a 40% jump in realised prices driving a 47% revenue increase. Underlying EBITDA soared 241%, underscoring operational efficiency and cost discipline.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

Cleo Diagnostics has chosen Bio-Techne’s next-generation Ella™ platform to enhance its ovarian cancer blood test, aiming for faster, more precise results and a streamlined path to FDA approval.

EV Resources has successfully produced its first metallic antimony ingots from the Los Lirios project in Mexico, validating a low-cost smelting process and advancing its strategy to supply the North American market.

Star Minerals has entered a strategic partnership with Catalyst Metals, securing a gold milling agreement for its Tumblegum South project and selling its West Bryah Basin copper-gold assets for $2.75 million. Catalyst also commits to a $1 million equity placement in Star Minerals, underpinning the company’s development plans.

Magellan Financial Group has reported a 5% rise in operating earnings per share and a striking 50% increase in its fully franked interim dividend, underpinned by strong contributions from strategic partnerships and disciplined capital management.

Magellan Financial Group reported a 27% drop in statutory net profit but maintained stable operating profit and increased earnings per share by 5%, supported by ongoing share buybacks. The company declared a fully franked interim dividend up 50%, reflecting confidence despite investment performance challenges.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.